Losartan raised serum levels of free IGF-I, which might contribute to the improvement of insulin resistance associated with losartan treatment.
Read More »New Wireless Device Aids in Diabetes Treatment
A new type of wireless medical device for managing diabetes has been developed by Philips and Cambridge Consultants.
Read More »Physical Activity Shrinks Abdominal Fat Cells
Physical activity may be especially helpful in reducing the size of fat cells around the waistline — more so than diet alone.
Read More »Major Cognitive Decline of 19 Years Linked to High Fat, High Copper Diet
A diet high in saturated and trans fats, coupled with a high intake of copper may be associated with a significantly accelerated rate of cognitive decline in older adults, a new study suggests.
Read More »A Designer Approach To Regulating Autoimmunity In Diabetes
Success has been demonstrated with one therapeutic approach in animals that shuts down the autoreactive T cells that attack beta islet cells.. https://www.diabetesincontrol.com/modules.php?name=News&file=article&sid=4043
Read More »Cognitive Dysfunction Linked With Poor Diabetes Control in Elderly
Elderly diabetics with poor glucose control have a high prevalence of undiagnosed cognitive dysfunction, depression and functional disabilities.
Read More »Prandin Offers Advantages in Elderly Diabetics
Fifty-one percent risk reduction for hypoglycemia over glyburide in elderly patients with type 2 or non-insulin dependent diabetes, treatment with the short-acting drug repaglinide (Prandin/NovoNorm)..
Read More »Obese Have Higher Cardiac Risk, but Better Treatment Outcomes
Obese individuals are at increased risk for developing an acute coronary syndrome (ACS), but because they are treated more aggressively than their lean counterparts, their outcomes are actually better.
Read More »Reducing Cholesterol Levels Can Reduce Stroke Risk by 16 Percent
An international team of researchers has completed a study that demonstrated a 16-percent reduction in secondary strokes and 35-percent reduction in coronary events in patients who previously experienced a stroke or TIA and were given 80 mg of
Read More »Januvia™ (Sitagliptin Phosphate) Receives Approval in Mexico
Approval of Januvia in Mexico Marks the First DPP-4 Inhibitor, a New Class of Oral Type 2 Diabetes Medicines, to be Approved in the World.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.